mlt004

Mark L. Tykocinski, MD

Contact Dr. Tykocinski

1025 Walnut Street
College Room 100
Philadelphia, PA 19107

(215) 955-1628

Most Recent Peer-reviewed Publications

  1. Toxicology and pharmacokinetic studies in mice and nonhuman primates of the nontoxic, efficient, targeted hexameric Fasl: CTLA4-FASL
  2. Dealing with deans and academic medical center leadership: Advice from leaders
  3. HuR contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells
  4. Can empathy, other personality attributes, and level of positive social influence in medical school identify potential leaders in medicine?
  5. Identifying potential engaging leaders within medical education: The role of positive influence on peers
  6. Cell Membrane Biology and Juxtacrine Signal Conversion
  7. Fn14•Trail Effectively Inhibits Hepatocellular Carcinoma Growth
  8. Signal Converter Proteins
  9. Energy transfer in "parasitic" cancer metabolism: Mitochondria are the powerhouse and Achilles' heel of tumor cells
  10. Inhibition of effector function but not T cell activation and increase in FoxP3 expression in T cells differentiated in the presence of PP14
  11. CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling
  12. Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis
  13. CTLA-4·Ig converts naive CD4+ CD25- T cells into CD4+CD25+ regulatory T cells
  14. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer
  15. CTLA-4·FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals
  16. OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-κB binding sites
  17. CD40·FasL inhibits human T cells: Evidence for an auto-inhibitory loop-back mechanism
  18. α2,6-Sialylation promotes binding of placental protein 14 via its Ca2+-dependent lectin activity: Insights into differential effects on CD45RO and CD45RA T cells
  19. CTLA-4·FasL inhibits allogeneic responses in vivo
  20. Pathology as the enabler of human research